Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2016

Voss Martin H, Hsieh James J

Abstract excerpt

mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney cancer, like a braided river. Clin Cancer Res; 22(10); 2320-2. ©2016 AACRSee...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Kidney Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Renal cell carcinoma treatment

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 26920890
DOI: 10.1158/1078-0432.CCR-16-0035
PMCID: PMC5431075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River.PMID 26920890Read ↗

Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancerSemantic proximity Read ↗

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapySemantic proximity Read ↗

Distinct Molecular Profiles and Drug Vulnerabilities in Pancreatic Metastases of Renal Cell CarcinomaSemantic proximity Read ↗

SnapShot: Renal Cell Carcinoma.Semantic proximity Read ↗

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology.Semantic proximity Read ↗

Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal CancersSemantic proximity Read ↗

Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic HorizonsSemantic proximity Read ↗

Toward a genome-based treatment landscape for renal cell carcinomaSemantic proximity Read ↗

Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.Semantic proximity Read ↗

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.Semantic proximity Read ↗

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Semantic proximity Read ↗

Pathway-centric multi-omics and functional precision medicine reveal shared drug vulnerabilities in heterogeneous adult Wilms tumorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.